Scientists from La Jolla Institute for Immunology, the J. Craig Venter Institute and the University of California, San Diego used existing data from known coronaviruses to predict which parts of SARS-CoV-2, a novel coronavirus that causes the respiratory illness COVID-19, are capable of activating the human immune system.
Existing data from known coronaviruses can be used to predict which parts of SARS-CoV-2 are capable of activating the human immune system. Image credit: Grifoni et al.
When the immune system encounters a bacterium or a virus, it zeroes in on tiny molecular features, so called epitopes, which allow cells of the immune system to distinguish between closely related foreign invaders and focus their attack.
Having a complete map of viral epitopes and their immunogenicity is critical to researchers attempting to design new or improved vaccines to protect against COVID-19.
“Right now, we have limited information about which pieces of the virus elicit a solid human response,” said La Jolla Institute for Immunology’s Professor Alessandro Sette, lead author of the study.
“Knowing the immunogenicity of certain viral regions, or in other words, which parts of the virus the immune system reacts to and how strongly, is of immediate relevance for the design of promising vaccine candidates and their evaluation.”
While scientists currently know very little about how the human immune system responds to SARS-CoV-2, the immune response to other coronaviruses has been studied and a significant amount of epitope data is available.
Four other coronaviruses are currently circulating in the human population. They cause generally mild symptoms and together they are responsible for an estimated one quarter of all seasonal colds.
But every few years, a new coronavirus emerges that causes severe disease as was the case with SARS-CoV in 2003 and MERS-CoV in 2008, and now SARS-CoV-2.
“SARS-CoV-2 is most closely related to SARS-CoV, which also happens to be the best characterized coronavirus in terms of epitopes,” said first author Dr. Alba Grifoni, also from La Jolla Institute for Immunology.
For the study, the researchers used available data from the Immune Epitope Database (IEDB), which contains over 600,000 known epitopes from some 3,600 different species, and the Virus Pathogen Resource (ViPR), a complementary repository of information about pathogenic viruses.
They compiled known epitopes from SARS-CoV and mapped the corresponding regions to SARS-CoV-2.
“We were able to map back 10 B cell epitopes to the new coronavirus and because of the overall high sequence similarity between SARS-CoV and SARS-CoV-2, there is a high likelihood that the same regions that are immunodominant in SARS-CoV are also dominant in SARS-CoV-2 is,” Dr. Grifoni said.
Five of these regions were found in the spike glycoprotein, which forms the ‘crown’ on the surface of the virus that gave coronaviruses their name; two in the membrane protein, which is embedded in the membrane that envelopes the protective protein shell around the viral genome and three in the nucleoprotein, which forms the shell.
In a similar analysis, T cell epitopes were also mostly associated with the spike glycoprotein and nucleoprotein.
In a completely different approach, the team used the epitope prediction algorithm hosted by the IEDB to predict linear B cell epitopes.
In a recent study, University of Texas at Austin’s Dr. Jason McLellan and colleagues determined the 3D structure of the spike proteins, which allowed the authors of the new study to take the protein’s spatial architecture into account when predicting epitopes. This approach confirmed two of the likely epitope regions they had predicted earlier.
To substantiate the SARS-CoV-2 T cell epitopes identified based on their homology to SARS-CoV, the scientists compared them with epitopes pinpointed by the Tepitool resource in the IEDB.
Using this approach, they were able verify 12 out of 17 SARS-CoV-2 T cell epitopes identified based on sequence similarities to SARS-CoV.
“The fact that we found that many B and T cell epitopes are highly conserved between SARS-CoV and SARS-CoV-2 provides a great starting point for vaccine development,” Professor Sette said.
“Vaccine strategies that specifically target these regions could generate immunity that’s not only cross-protective but also relatively resistant to ongoing virus evolution.”
The results appear in the journal Cell Host & Microbe.
_____
Alba Grifoni et al. 2020. A sequence homology and bioinformatic approach can predictcandidate targets for immune responses to SARS-CoV-2. Cell Host & Microbe, in press; doi: 10.1016/j.chom.2020.03.002
